MARKET

CELG-RT

CELG-RT

Bristol-Myers Squibb Company Celegne Contingent Value Rights
NYSE
0.1277
+0.0064
+5.28%
Closed 16:00 12/06 EST
OPEN
0.1211
PREV CLOSE
0.1212
HIGH
0.1277
LOW
0.1006
VOLUME
12.04K
TURNOVER
618
52 WEEK HIGH
0.2500
52 WEEK LOW
0.0656
MARKET CAP
90.81M
P/E (TTM)
0.0159
1D
5D
1M
3M
1Y
5Y
Pfizer's bowel disease drug succeeds in second late-stage study
reuters.com · 03/29 10:45
Bristol Myers sees slight 2022 sales growth due to sharply lower Revlimid sales
reuters.com · 01/10 11:45
UPDATE 1-U.S. FTC okays changes to Bristol Meyers Squibb divestiture agreement
reuters.com · 11/12/2021 21:57
BRIEF-Exscientia Files For U.S. IPO
reuters.com · 09/10/2021 15:56
U.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy
reuters.com · 03/27/2021 04:47
Amgen second-quarter revenue rises 6%, shares fall 2%
Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to...
Reuters · 07/28/2020 22:37
US syndicated loan issuance tumbles as confidence drops
Trade wars, uncertainty about Brexit and a potential looming recession reduced US syndicated lending to US$2.11trn, an abysmal 20% drop from the prior record-year tally.
Reuters · 01/03/2020 17:57
Investment grade market was liquid, stable and muted in 2019
Issuance in the investment grade loan market was strong this year, though slightly down from 2018, supported by jumbo merger and acquisition (M&A) transactions, as the market proved its capacity to continue to fund big-ticket companies.
Reuters · 12/19/2019 17:26
More
About CELG-RT
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Webull offers kinds of Celgene Corporation stock information, including NYSE:CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELG-RT stock methods without spending real money on the virtual paper trading platform.